Biogen (BIIB) Net Profit Margin: History & Chart

Biogen Inc.(BIIB)

Drug Manufacturers - General · Cambridge, MA

$213.70-7.13 (-3.23%)

Delayed quote: Sep 8, 2026, 2:55 PM EDT

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

BIIB Net Profit Margin Metrics

NET PROFIT MARGIN

8.39%

NET PROFIT MARGIN AVG TTM

11.47%

NET PROFIT MARGIN AVG 3Y

12.81%

NET PROFIT MARGIN AVG 5Y

13.55%

NET PROFIT MARGIN AVG 10Y

23.14%

NET PROFIT MARGIN AVG 15Y

25.00%

NET PROFIT MARGIN AVG 20Y

24.85%

CURRENT VS TTM AVG

-26.83%

CURRENT VS 3Y AVG

-34.52%

CURRENT VS 5Y AVG

-38.07%

CURRENT VS 10Y AVG

-63.74%

CURRENT VS 15Y AVG

-66.44%

CURRENT VS 20Y AVG

-66.23%

SECTOR MEDIAN · HEALTHCARE

8.98%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

-6.57%

vs the sector median at left

NAME	MARKET CAP	NET PROFIT MARGIN	TTM	3Y	5Y
Biogen Inc. (BIIB)	$31.58B	8.39%	11.47%	12.81%	13.55%
DexCom, Inc. (DXCM)vs ›	$32.07B	20.12%	16.12%	14.73%	15.57%
Zoetis Inc. (ZTS)vs ›	$31.04B	27.49%	27.55%	27.17%	26.57%
Centene Corp. (CNC)vs ›	$32.22B	-2.63%	-0.70%	0.29%	0.65%
ResMed Inc. (RMD)vs ›	$32.26B	26.94%	27.08%	24.30%	22.30%
GE HealthCare Technologies Inc. (GEHC)vs ›	$30.35B	7.86%	10.12%	9.68%	22.03%
Waters Corporation (WAT)vs ›	$30.19B	3.58%	20.93%	21.85%	22.39%
Medline Inc. (MDLN)vs ›	$29.75B	2.31%	4.39%	2.42%	2.42%
Alcon Inc. (ALC)vs ›	$33.80B	5.92%	9.84%	8.46%	5.10%
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$35.17B	16.82%	-1.96%	-34.26%	-68.70%

NAME

MARKET CAP

NET PROFIT MARGIN

TTM

Biogen Inc. (BIIB)

$31.58B

8.39%

11.47%

12.81%

13.55%

DexCom, Inc. (DXCM)vs ›

$32.07B

20.12%

16.12%

14.73%

15.57%

Zoetis Inc. (ZTS)vs ›

$31.04B

27.49%

27.55%

27.17%

26.57%

Centene Corp. (CNC)vs ›

$32.22B

-2.63%

-0.70%

0.29%

0.65%

ResMed Inc. (RMD)vs ›

$32.26B

26.94%

27.08%

24.30%

22.30%

GE HealthCare Technologies Inc. (GEHC)vs ›

$30.35B

7.86%

10.12%

9.68%

22.03%

Waters Corporation (WAT)vs ›

$30.19B

3.58%

20.93%

21.85%

22.39%

Medline Inc. (MDLN)vs ›

$29.75B

2.31%

4.39%

2.42%

Alcon Inc. (ALC)vs ›

$33.80B

5.92%

9.84%

8.46%

5.10%

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$35.17B

16.82%

-1.96%

-34.26%

-68.70%

Net Profit Margin FAQ

What is the net profit margin for Biogen Inc. (BIIB)?

The net profit margin for BIIB stock is 8.39%.

Is Biogen Inc.'s net profit margin high or low?

The net profit margin of 8.39% is 38% below its 5-year average of 13.55%, near the low end of its 5-year range (-2.69%–45.23%).

What is the TTM average net profit margin for Biogen Inc. (BIIB)?

The TTM average net profit margin for BIIB stock is 11.47%.

What is the 3Y average net profit margin for Biogen Inc. (BIIB)?

The 3Y average net profit margin for BIIB stock is 12.81%.

What is the 5Y average net profit margin for Biogen Inc. (BIIB)?

The 5Y average net profit margin for BIIB stock is 13.55%.

What is the 10Y average net profit margin for Biogen Inc. (BIIB)?

The 10Y average net profit margin for BIIB stock is 23.14%.

What is the 15Y average net profit margin for Biogen Inc. (BIIB)?

The 15Y average net profit margin for BIIB stock is 25.00%.

What is the 20Y average net profit margin for Biogen Inc. (BIIB)?

The 20Y average net profit margin for BIIB stock is 24.85%.

DATE	NET PROFIT MARGIN
2026-06-30	3.56%
2026-03-31	12.89%
2025-12-31	-2.12%
2025-09-30	19.00%
2025-06-30	24.00%
2025-03-31	9.89%
2024-12-31	10.86%
2024-09-30	15.76%
2024-06-30	23.68%
2024-03-31	17.18%
2023-12-31	10.46%
2023-09-30	-2.69%
2023-06-30	24.09%
2023-03-31	15.75%
2022-12-31	21.64%
2022-09-30	45.23%
2022-06-30	40.86%
2022-03-31	12.00%
2021-12-31	13.47%
2021-09-30	11.85%
2021-06-30	16.16%
2021-03-31	15.23%
2020-12-31	12.55%
2020-09-30	20.78%
2020-06-30	41.89%
2020-03-31	39.59%
2019-12-31	39.21%
2019-09-30	42.94%
2019-06-30	41.31%
2019-03-31	40.37%
2018-12-31	26.85%
2018-09-30	42.00%
2018-06-30	25.82%
2018-03-31	37.46%
2017-12-31	-8.99%
2017-09-30	39.84%
2017-06-30	28.03%
2017-03-31	26.60%
2016-12-31	22.60%
2016-09-30	34.94%
2016-06-30	36.27%
2016-03-31	35.61%
2015-12-31	29.29%
2015-09-30	34.76%
2015-06-30	35.78%
2015-03-31	32.19%
2014-12-31	33.46%
2014-09-30	34.12%
2014-06-30	29.51%
2014-03-31	22.54%
2013-12-31	23.26%
2013-09-30	26.68%
2013-06-30	28.49%
2013-03-31	30.16%
2012-12-31	20.60%
2012-09-30	28.75%
2012-06-30	27.22%
2012-03-31	23.43%
2011-12-31	22.63%
2011-09-30	33.72%
2011-06-30	23.83%
2011-03-31	24.42%
2010-12-31	19.71%
2010-09-30	21.61%
2010-06-30	24.20%
2010-03-31	19.57%
2009-12-31	27.12%
2009-09-30	24.78%
2009-06-30	13.07%
2009-03-31	23.54%
2008-12-31	19.33%
2008-09-30	18.92%
2008-06-30	20.77%
2008-03-31	17.34%
2007-12-31	22.52%
2007-09-30	15.15%
2007-06-30	24.05%
2007-03-31	18.40%
2006-12-31	-105.88%
2006-09-30	22.29%
2006-06-30	-25.85%
2006-03-31	20.09%
2005-12-31	-73.08%
2005-09-30	4.55%
2005-06-30	5.69%
2005-03-31	7.38%
2004-12-31	-102.60%
2004-09-30	6.76%
2004-06-30	0.15%
2004-03-31	-7.60%
2003-12-31	340.42%
2003-09-30	32.84%
2003-06-30	23.28%
2003-03-31	35.14%
2002-12-31	13.70%
2002-09-30	14.64%

DATE

NET PROFIT MARGIN

2026-06-30

3.56%

2026-03-31

12.89%

2025-12-31

-2.12%

2025-09-30

19.00%

2025-06-30

24.00%

2025-03-31

9.89%

2024-12-31

10.86%

2024-09-30

15.76%

2024-06-30

23.68%

2024-03-31

17.18%

2023-12-31

10.46%

2023-09-30

-2.69%

2023-06-30

24.09%

2023-03-31

15.75%

2022-12-31

21.64%

2022-09-30

45.23%

2022-06-30

40.86%

2022-03-31

12.00%

2021-12-31

13.47%

2021-09-30

11.85%

2021-06-30

16.16%

2021-03-31

15.23%

2020-12-31

12.55%

2020-09-30

20.78%

2020-06-30

41.89%

2020-03-31

39.59%

2019-12-31

39.21%

2019-09-30

42.94%

2019-06-30

41.31%

2019-03-31

40.37%

2018-12-31

26.85%

2018-09-30

42.00%

2018-06-30

25.82%

2018-03-31

37.46%

2017-12-31

-8.99%

2017-09-30

39.84%

2017-06-30

28.03%

2017-03-31

26.60%

2016-12-31

22.60%

2016-09-30

34.94%

2016-06-30

36.27%

2016-03-31

35.61%

2015-12-31

29.29%

2015-09-30

34.76%

2015-06-30

35.78%

2015-03-31

32.19%

2014-12-31

33.46%

2014-09-30

34.12%

2014-06-30

29.51%

2014-03-31

22.54%

2013-12-31

23.26%

2013-09-30

26.68%

2013-06-30

28.49%

2013-03-31

30.16%

2012-12-31

20.60%

2012-09-30

28.75%

2012-06-30

27.22%

2012-03-31

23.43%

2011-12-31

22.63%

2011-09-30

33.72%

2011-06-30

23.83%

2011-03-31

24.42%

2010-12-31

19.71%

2010-09-30

21.61%

2010-06-30

24.20%

2010-03-31

19.57%

2009-12-31

27.12%

2009-09-30

24.78%

2009-06-30

13.07%

2009-03-31

23.54%

2008-12-31

19.33%

2008-09-30

18.92%

2008-06-30

20.77%

2008-03-31

17.34%

2007-12-31

22.52%

2007-09-30

15.15%

2007-06-30

24.05%

2007-03-31

18.40%

2006-12-31

-105.88%

2006-09-30

22.29%

2006-06-30

-25.85%

2006-03-31

20.09%

2005-12-31

-73.08%

2005-09-30

4.55%

2005-06-30

5.69%

2005-03-31

7.38%

2004-12-31

-102.60%

2004-09-30

6.76%

2004-06-30

0.15%

2004-03-31

-7.60%

2003-12-31

340.42%

2003-09-30

32.84%

2003-06-30

23.28%

2003-03-31

35.14%

2002-12-31

13.70%

2002-09-30

14.64%

Net Profit Margin: 8.39%

BIIB Profit Margin

BIIB Average Net Profit Margin Chart

BIIB Current vs Average Net Profit Margin Chart

BIIB Net Profit Margin Metrics

BIIB Competitors' Net Profit Margin

Margin Comparison

Net Profit Margin Formula & Definition

Net Profit Margin FAQ

BIIB Net Profit Margin History

Related Metrics